Micronization of cilostazol using supercritical antisolvent (SAS) process: Effect of process parameters

被引:95
作者
Kim, Min-Soo
Lee, Sibeum
Park, Jeong-Sook
Woo, Jong-Soo
Hwang, Sung-Joo
机构
[1] Chungnam Natl Univ, Coll Pharm, Natl Res Lab Pharmacet Technol, Taejon 305764, South Korea
[2] Hanmi Pharmaceut Co Ltd, Kyonggi Do 445910, South Korea
关键词
cilostazol; supercritical antisolvent; micronization; poorly water-soluble drug;
D O I
10.1016/j.powtec.2007.02.029
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
The aim of this study was to improve dissolution rate of poorly water-soluble drug, cilostazol, using supercritical antisolvent (SAS) process. The effect of process variables, such as pressure, temperature, drug concentration, type of solvents, feed rate ratio of CO2/drug solution, on drug particle formation during SAS process was investigated. Particles with mean particle size ranging between 0.90 and 4.52 gin were obtained by varying process parameters such as precipitation vessel pressure and temperature, drug solution concentration, solvent type, feed rate ratio of CO2/drug solution. In particular, mean particle size and distribution were markedly influenced by drug solution concentration during SAS process. Moreover, the drug did not change its crystal form and the operating parameters might control the 'crystal texture' due to the change in crystallinity and preferred orientation during SAS process, as confirmed by differential scanning calorimetry and powder X-ray diffraction study. In addition, the dissolution rate of drug precipitated using SAS process was highly increased in comparison with unprocessed drug. Therefore, it is concluded that the dissolution rate of drug is significantly increased by micronization of cilostazol, leading to the reduction in particle size and increased specific surface area after SAS process. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:64 / 70
页数:7
相关论文
共 35 条
[1]   Experimental study of the GAS process for producing microparticles of beclomethasone-17,21-dipropionate suitable for pulmonary delivery [J].
Bakhbakhi, Y ;
Charpentier, PA ;
Rohani, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 309 (1-2) :71-80
[2]   High-pressure (vapor plus liquid) equilibrium in binary mixtures of (carbon dioxide plus water or acetic acid) at temperatures from 313 to 353 K [J].
Bamberger, A ;
Sieder, G ;
Maurer, G .
JOURNAL OF SUPERCRITICAL FLUIDS, 2000, 17 (02) :97-110
[3]   Densities and P-x-y diagrams for carbon dioxide dissolution in methanol, ethanol, and acetone mixtures [J].
Chang, CJ ;
Day, CY ;
Ko, CM ;
Chiu, KL .
FLUID PHASE EQUILIBRIA, 1997, 131 (1-2) :243-258
[4]   Recrystallization of andrographolide using the supercritical fluid antisolvent process [J].
Chen, KX ;
Zhang, XY ;
Pan, J ;
Yin, WH .
JOURNAL OF CRYSTAL GROWTH, 2005, 274 (1-2) :226-232
[5]  
CULLITY BD, 1978, CULLITY ELEMENTS XRA, P127
[6]   Polymorphic properties of micronized carbamazepine produced by RESS [J].
Gosselin, PM ;
Thibert, R ;
Preda, M ;
McMullen, JN .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 252 (1-2) :225-233
[7]   Fine particle formation using supercritical fluids [J].
Hakuta, Y ;
Hayashi, H ;
Arai, K .
CURRENT OPINION IN SOLID STATE & MATERIALS SCIENCE, 2003, 7 (4-5) :341-351
[8]   Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids [J].
Jun, SW ;
Kim, MS ;
Jo, GH ;
Lee, S ;
Woo, JS ;
Park, JS ;
Hwang, SJ .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (12) :1529-1537
[9]   Particle design using supercritical fluids: Literature and patent survey [J].
Jung, J ;
Perrut, M .
JOURNAL OF SUPERCRITICAL FLUIDS, 2001, 20 (03) :179-219
[10]  
KIMURA Y, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1144